Abstract: ［Abstract］〓Objective〖HTSS〗〓To explore the expression and clinical significance of serum levels of vascular endothelial growth factor (VEGF) in breast cancer.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 146 cases of breast cancer patients were selected as experimental group and 30 cases of benign breast disease as control group. Enzyme linked immunosorbent assay method was used to determine serum VEGF levels, the level of serum VEGF in the two groups was analyzed, and serum VEGF levels in patients with different clinical factors(age, histological grade, TNM staging, human epidermal growth factor receptor2, estrogen receptor, progesterone receptor) in the experimental group were compared.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The expression of serum VEGF in breast cancer patients was significantly higher than that in benign breast disease patients, and the difference was statistically significant(P＜005). The higher the histological grade, the later the TNM stage, the higher the human epidermal growth factor receptor2 positive state, the higher the serum VEGF expression level. Differences are statistically significant(P＜005). There was no significant difference in serum VEGF expression among breast cancer patients with different ages, estrogen receptor and progesterone receptor(P＞005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Serum VEGF is highly expressed in breast cancer patients and is related to the progression, metastasis and prognosis of breast cancer. Serum VEGF can provide a theoretical basis for the early diagnosis, targeted therapy and prognosis evaluation of breast cancer.

Key words: breast neoplasms, vascular endothelial growth factors, enzymelinked immunosorbent assay